Dear Colleagues,
 
At IBET we have been involved, together with CIRAD (Dr. Geneviève Libeau) in increasing the thermal stability of the current PPR vaccine. This started with the EU MARKVAC project and continued more recently with the frame of the VACNADA project from GALVMED.
 
A candidate formulation (Tris/Trehalose) for PPR vaccine using the Nig75/1 strain has been evaluated at IBET and transferred to one of the vaccine producing laboratories, NVI in Ethiopia (Dr. Martha Yami). All the collected results have showed that changing the vaccine formulation from the Weybridge medium to a Tris/Trehalose formulation increases the thermal stability of the current PPR vaccine, not only in a research laboratory context but also in a producing laboratory. The results obtained at NVI were presented in the second meeting of the Global PPR Research Alliance held in 2013 as a poster and are now accepted for publication in Vaccine. We agree that the use of a thermo-stable PPR vaccine will benefit in the eradication of this disease. We hope that our experience and knowledge could contribute to achieve that objective.
 
For more information, if someone is interested, we can send the pdfs of the related publications:
Best regards,
 
Manuel Carrondo

-- 
PS: Please acknowledge reception of this email
 
Manuel J T Carrondo, PhD
Professor of Chemical and Biochemical Engineering, FCT-UNL
Director, IBET
Apartado 12
2780-901 OEIRAS
PORTUGAL
EMAIL: [log in to unmask]
PHONE: 351 21 4469362
FAX: 351 21 4421161
www.ibet.pt
 
PA to Prof. Carrondo: Ana Margarida Machado
email: [log in to unmask]


To unsubscribe from the FAO-AnimalHealth-L list, click the following link:
https://listserv.fao.org/cgi-bin/wa?SUBED1=FAO-AnimalHealth-L&A=1